Catalyst Total Debt To Capitalization from 2010 to 2025

CPRX Stock  USD 23.06  0.34  1.45%   
Catalyst Pharmaceuticals Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization will likely drop to 0.01 in 2025. During the period from 2010 to 2025, Catalyst Pharmaceuticals Total Debt To Capitalization regression line of annual values had r-squared of  0.06 and arithmetic mean of  0.01. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.008178
Current Value
0.007658
Quarterly Volatility
0.00364867
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 376 M or Operating Income of 104.8 M, as well as many indicators such as Price To Sales Ratio of 4.9, Dividend Yield of 0.0 or PTB Ratio of 5.03. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Latest Catalyst Pharmaceuticals' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Catalyst Pharmaceuticals over the last few years. It is Catalyst Pharmaceuticals' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Pretty Stable
   Total Debt To Capitalization   
       Timeline  

Catalyst Total Debt To Capitalization Regression Statistics

Arithmetic Mean0.01
Geometric Mean0.01
Coefficient Of Variation45.00
Mean Deviation0
Median0.01
Standard Deviation0
Sample Variance0.000013
Range0.0183
R-Value0.24
Mean Square Error0.000013
R-Squared0.06
Significance0.37
Slope0.0002
Total Sum of Squares0.0002

Catalyst Total Debt To Capitalization History

2025 0.007658
2024 0.008178
2023 0.009087
2022 0.0128
2021 0.0185
2020 1.7E-4

About Catalyst Pharmaceuticals Financial Statements

Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Debt To Capitalization 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.